^
    Back
    Association details:
    Biomarker:STRN-ALK fusion + MET amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor) +
    Ensacove (ensartinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Cell Mol Med
    Title:

    Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review

    Published date:
    09/19/2021
    Excerpt:
    Herein, two advanced NSCLC patients….Molecular profiling using next-generation sequencing (NGS) further revealed a striatin (STRN)-ALK fusion in the first patient accompanied by MET amplification, and a LIM domain only protein 7 (LMO7)-ALK fusion in another patient without any other known oncogenic alterations. Both patients demonstrated improved survival after they switched to second-line crizotinib (PFS: 11 months) and ensartinib (PFS: 18 months), respectively, up till the last follow-up assessment.
    DOI:
    https://doi.org/10.1111/jcmm.16897